HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INBX
Inhibrx Biosciences, Inc.
There isn't enough reported data to score INBX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INBX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INBX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INBX PE Valuation
INBX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INBX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INBX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INBX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$8.88 | +$1.70 |
| Q1 2026 | -$8.39 | -107% |
| Q4 2025 | -$9.04 | -108% |
| Q3 2025 | -$10.02 | -108% |
| Q2 2025 | -$10.58 | -109% |
| Q1 2025 | $116.75 | +$122.10 |
| Q4 2024 | $118.11 | +$123.14 |
| Q3 2024 | $119.47 | +$123.72 |
INBX is still losing money, but less than at its worst: $8.88 per share over the past year, against $10.58 at its worst in mid-2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
INBX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $1.3M | +1200% |
| Q4 2024 | $100K | -94% |
| Q2 2024 | $100K | +233% |
| Q4 2023 | $1.6M | +496% |
| Q3 2023 | $119K | -57% |
| Q2 2023 | $30K | -96% |
| Q1 2023 | $17K | -98% |
| Q4 2022 | $274K | -90% |
INBX's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -2107% | +158791 points |
| Q4 2024 | -49928% | -44525 points |
| Q2 2024 | -160898% | -23101 points |
| Q4 2023 | -5403% | +7553 points |
| Q3 2023 | -38510% | -27718 points |
| Q2 2023 | -137797% | -132931 points |
| Q1 2023 | -257447% | -254274 points |
| Q4 2022 | -12956% | -12271 points |
INBX's operating margin was −2107% last quarter, up 36403 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INBX on cash generation, producing positive trailing cash flow while its opponent burns cash.
INBX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29.9M | +$36K |
| Q1 2026 | -$38M | -$2.1M |
| Q4 2025 | -$30.1M | +$13.6M |
| Q3 2025 | -$33.8M | -$3.3M |
| Q1 2025 | -$35.9M | +$28.3M |
| Q4 2024 | -$43.7M | +$16.5M |
| Q3 2024 | -$30.5M | +$24.5M |
| Q1 2024 | -$64.2M | -$37.2M |
INBX has burned cash in almost every quarter: −$132M over the past year, against −$140M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INBX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INBX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +84K shares |
| 1 year | +1.3% | +201K shares |
| 3 years | -64% | -28M shares |
| 5 years | -58% | -22M shares |
INBX has 16M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INBX Net Leverage
INBX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INBX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.6 | Neutral |
| Stochastic | 22.7 | Neutral |
INBX's weekly RSI is 48 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INBX PE vs Healthcare Sector
| Metric | INBX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INBX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
INBX has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus INBX above 1 of 4.
INBX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $89.9 | 2.3% below |
| 20 week MA | $95.2 | 7.8% below |
| 50 week MA | $89.6 | 2.1% below |
| 100 week MA | $57.5 | 53% above |
INBX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 53% above its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INBX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $34.1 | $15.0 | -56% |
| 2025 | $15.0 | $80.2 | +434% |
| 2026 YTD | $80.2 | $87.8 | +9.4% |
INBX has the edge over HIMS on returns for 2026, with the stronger performance.